Plasmablastic Lymphoma: Past, Present, and Future
Clin Lymphoma Myeloma Leuk. 2023 Jun 14:S2152-2650(23)00181-7. doi: 10.1016/j.clml.2023.05.014. Online ahead of print.ABSTRACTPlasmablastic Lymphoma is a rare large B-cell lymphoma with unique immunohistochemical and morphological features. It was most commonly associated with HIV infection; however, it's now seen in other immunosuppressed states like autoimmune conditions, post-transplant settings, and even in elderly immunocompetent individuals. Although rare, it is an aggressive lymphoma with unfavorable outcomes. The aim of this manuscript is to have an in-depth review of the current knowledge of epidemiology, pathophy...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Supreet Kaur Sudarsan Kollimuttathuillam Source Type: research
Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis
Clin Lymphoma Myeloma Leuk. 2023 Jun 26:S2152-2650(23)00196-9. doi: 10.1016/j.clml.2023.06.008. Online ahead of print.ABSTRACTPrimary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin's lymphoma involving the brain, cerebrospinal fluid, spinal cord and eyes. Rituximab has played a prominent role in the treatment of non-Hodgkin's B-cell lymphomas, including aggressive diffuse large B lymphoma. However, as a macromolecular drug, the role of rituximab in the treatment of PCNSL has been controversial. In this systematic review and meta-analysis, we evaluated the role of rituximab in the treatment of PCNSL. ...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Yuhang Zhang Zhihe Liu Chengwen Gao Haiyan Bian Yushuo Ma Fanjing Jing Xia Zhao Source Type: research
Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by < sup > 18 < /sup > F-FDG PET/CT Imaging Following CAR-T Therapy
CONCLUSION: We demonstrate that a higher day 28 SUVmax was significantly higher in those with a B-OR of PR and in our modeling, a lower day 28 SUVmax may predict favorable PFS and OS. Additionally, lower TMV, both at baseline and day 28, may also be predictive of longer PFS and OS, while lower TLG at baseline, but not day 28 is significantly associated with a B-OR of CR. While further study is warranted, these imaging biomarkers may allow for early identification of those with a day 28 PR at highest risk for relapse leading to early intervention to improve long term outcomes.PMID:37453865 | DOI:10.1016/j.clml.2023.06.005 (...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Forat Lutfi Olga Goloubeva Amer Kowatli Anton Gryaznov Dong W Kim Rohan Dureja Philip Margiotta Lisa R Matsumoto Ali Bukhari Nausheen Ahmed Muhammad Umair Mushtaq Jennie Y Law Seung T Lee Mehmet H Kocoglu Djordje Atanackovic Jean A Yared Nancy M Hardy Jos Source Type: research
Plasmablastic Lymphoma: Past, Present, and Future
Clin Lymphoma Myeloma Leuk. 2023 Jun 14:S2152-2650(23)00181-7. doi: 10.1016/j.clml.2023.05.014. Online ahead of print.ABSTRACTPlasmablastic Lymphoma is a rare large B-cell lymphoma with unique immunohistochemical and morphological features. It was most commonly associated with HIV infection; however, it's now seen in other immunosuppressed states like autoimmune conditions, post-transplant settings, and even in elderly immunocompetent individuals. Although rare, it is an aggressive lymphoma with unfavorable outcomes. The aim of this manuscript is to have an in-depth review of the current knowledge of epidemiology, pathophy...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Supreet Kaur Sudarsan Kollimuttathuillam Source Type: research
Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis
Clin Lymphoma Myeloma Leuk. 2023 Jun 26:S2152-2650(23)00196-9. doi: 10.1016/j.clml.2023.06.008. Online ahead of print.ABSTRACTPrimary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin's lymphoma involving the brain, cerebrospinal fluid, spinal cord and eyes. Rituximab has played a prominent role in the treatment of non-Hodgkin's B-cell lymphomas, including aggressive diffuse large B lymphoma. However, as a macromolecular drug, the role of rituximab in the treatment of PCNSL has been controversial. In this systematic review and meta-analysis, we evaluated the role of rituximab in the treatment of PCNSL. ...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Yuhang Zhang Zhihe Liu Chengwen Gao Haiyan Bian Yushuo Ma Fanjing Jing Xia Zhao Source Type: research
Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by < sup > 18 < /sup > F-FDG PET/CT Imaging Following CAR-T Therapy
CONCLUSION: We demonstrate that a higher day 28 SUVmax was significantly higher in those with a B-OR of PR and in our modeling, a lower day 28 SUVmax may predict favorable PFS and OS. Additionally, lower TMV, both at baseline and day 28, may also be predictive of longer PFS and OS, while lower TLG at baseline, but not day 28 is significantly associated with a B-OR of CR. While further study is warranted, these imaging biomarkers may allow for early identification of those with a day 28 PR at highest risk for relapse leading to early intervention to improve long term outcomes.PMID:37453865 | DOI:10.1016/j.clml.2023.06.005 (...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Forat Lutfi Olga Goloubeva Amer Kowatli Anton Gryaznov Dong W Kim Rohan Dureja Philip Margiotta Lisa R Matsumoto Ali Bukhari Nausheen Ahmed Muhammad Umair Mushtaq Jennie Y Law Seung T Lee Mehmet H Kocoglu Djordje Atanackovic Jean A Yared Nancy M Hardy Jos Source Type: research
Plasmablastic Lymphoma: Past, Present, and Future
Clin Lymphoma Myeloma Leuk. 2023 Jun 14:S2152-2650(23)00181-7. doi: 10.1016/j.clml.2023.05.014. Online ahead of print.ABSTRACTPlasmablastic Lymphoma is a rare large B-cell lymphoma with unique immunohistochemical and morphological features. It was most commonly associated with HIV infection; however, it's now seen in other immunosuppressed states like autoimmune conditions, post-transplant settings, and even in elderly immunocompetent individuals. Although rare, it is an aggressive lymphoma with unfavorable outcomes. The aim of this manuscript is to have an in-depth review of the current knowledge of epidemiology, pathophy...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Supreet Kaur Sudarsan Kollimuttathuillam Source Type: research
Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis
Clin Lymphoma Myeloma Leuk. 2023 Jun 26:S2152-2650(23)00196-9. doi: 10.1016/j.clml.2023.06.008. Online ahead of print.ABSTRACTPrimary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin's lymphoma involving the brain, cerebrospinal fluid, spinal cord and eyes. Rituximab has played a prominent role in the treatment of non-Hodgkin's B-cell lymphomas, including aggressive diffuse large B lymphoma. However, as a macromolecular drug, the role of rituximab in the treatment of PCNSL has been controversial. In this systematic review and meta-analysis, we evaluated the role of rituximab in the treatment of PCNSL. ...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Yuhang Zhang Zhihe Liu Chengwen Gao Haiyan Bian Yushuo Ma Fanjing Jing Xia Zhao Source Type: research
Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by < sup > 18 < /sup > F-FDG PET/CT Imaging Following CAR-T Therapy
CONCLUSION: We demonstrate that a higher day 28 SUVmax was significantly higher in those with a B-OR of PR and in our modeling, a lower day 28 SUVmax may predict favorable PFS and OS. Additionally, lower TMV, both at baseline and day 28, may also be predictive of longer PFS and OS, while lower TLG at baseline, but not day 28 is significantly associated with a B-OR of CR. While further study is warranted, these imaging biomarkers may allow for early identification of those with a day 28 PR at highest risk for relapse leading to early intervention to improve long term outcomes.PMID:37453865 | DOI:10.1016/j.clml.2023.06.005 (...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Forat Lutfi Olga Goloubeva Amer Kowatli Anton Gryaznov Dong W Kim Rohan Dureja Philip Margiotta Lisa R Matsumoto Ali Bukhari Nausheen Ahmed Muhammad Umair Mushtaq Jennie Y Law Seung T Lee Mehmet H Kocoglu Djordje Atanackovic Jean A Yared Nancy M Hardy Jos Source Type: research
Plasmablastic Lymphoma: Past, Present, and Future
Clin Lymphoma Myeloma Leuk. 2023 Jun 14:S2152-2650(23)00181-7. doi: 10.1016/j.clml.2023.05.014. Online ahead of print.ABSTRACTPlasmablastic Lymphoma is a rare large B-cell lymphoma with unique immunohistochemical and morphological features. It was most commonly associated with HIV infection; however, it's now seen in other immunosuppressed states like autoimmune conditions, post-transplant settings, and even in elderly immunocompetent individuals. Although rare, it is an aggressive lymphoma with unfavorable outcomes. The aim of this manuscript is to have an in-depth review of the current knowledge of epidemiology, pathophy...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Supreet Kaur Sudarsan Kollimuttathuillam Source Type: research
Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis
Clin Lymphoma Myeloma Leuk. 2023 Jun 26:S2152-2650(23)00196-9. doi: 10.1016/j.clml.2023.06.008. Online ahead of print.ABSTRACTPrimary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin's lymphoma involving the brain, cerebrospinal fluid, spinal cord and eyes. Rituximab has played a prominent role in the treatment of non-Hodgkin's B-cell lymphomas, including aggressive diffuse large B lymphoma. However, as a macromolecular drug, the role of rituximab in the treatment of PCNSL has been controversial. In this systematic review and meta-analysis, we evaluated the role of rituximab in the treatment of PCNSL. ...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Yuhang Zhang Zhihe Liu Chengwen Gao Haiyan Bian Yushuo Ma Fanjing Jing Xia Zhao Source Type: research
SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Adults: Therapeutic Options and Challenges in 2023
Clin Lymphoma Myeloma Leuk. 2023 Jun 27:S2152-2650(23)00195-7. doi: 10.1016/j.clml.2023.06.007. Online ahead of print.ABSTRACTThe therapeutic landscape of Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) for adults has dramatically changed over the past 2 decades; the emergence of newer generations of tyrosine kinase inhibitors and incorporation of targeted immunotherapies into front-line therapy have significantly improved outcomes to the point where an argument can be made that this entity may no longer be considered a high-risk ALL subgroup. In this review article, we discuss different front-line regi...
Source: Clinical Lymphoma and Myeloma - July 12, 2023 Category: Cancer & Oncology Authors: Zaid Abdel Rahman Partow Kebriaei Source Type: research
SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Adults: Therapeutic Options and Challenges in 2023
Clin Lymphoma Myeloma Leuk. 2023 Jun 27:S2152-2650(23)00195-7. doi: 10.1016/j.clml.2023.06.007. Online ahead of print.ABSTRACTThe therapeutic landscape of Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) for adults has dramatically changed over the past 2 decades; the emergence of newer generations of tyrosine kinase inhibitors and incorporation of targeted immunotherapies into front-line therapy have significantly improved outcomes to the point where an argument can be made that this entity may no longer be considered a high-risk ALL subgroup. In this review article, we discuss different front-line regi...
Source: Clinical Lymphoma and Myeloma - July 12, 2023 Category: Cancer & Oncology Authors: Zaid Abdel Rahman Partow Kebriaei Source Type: research
SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Adults: Therapeutic Options and Challenges in 2023
Clin Lymphoma Myeloma Leuk. 2023 Jun 27:S2152-2650(23)00195-7. doi: 10.1016/j.clml.2023.06.007. Online ahead of print.ABSTRACTThe therapeutic landscape of Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) for adults has dramatically changed over the past 2 decades; the emergence of newer generations of tyrosine kinase inhibitors and incorporation of targeted immunotherapies into front-line therapy have significantly improved outcomes to the point where an argument can be made that this entity may no longer be considered a high-risk ALL subgroup. In this review article, we discuss different front-line regi...
Source: Clinical Lymphoma and Myeloma - July 12, 2023 Category: Cancer & Oncology Authors: Zaid Abdel Rahman Partow Kebriaei Source Type: research
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
CONCLUSION: Selinexor-based regimens may offer effective and well-tolerated therapy to patients with relapsed and/or refractory MM who had disease previously exposed or refractory to αCD38 mAb therapy and could help address the unmet clinical need in these high-risk patients.PMID:37393120 | DOI:10.1016/j.clml.2023.06.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Gary J Schiller Brea C Lipe Nizar J Bahlis Sascha A Tuchman William I Bensinger Heather J Sutherland Suzanne Lentzsch Muhamed Baljevic Darrell White Rami Kotb Christine I Chen Adriana Rossi Noa Biran Richard LeBlanc Sebastian Grosicki Maurizio Martelli Eb Source Type: research
